Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.61 |
| ▸ | ALPI | P09923 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | XIAP | P98170 | 1/20 | 0.61 |
| ▸ | PTPRC | P08575 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | FYN | P06241 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | TPH1 | P17752 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL93952 | 1.00 | SLC7A5 (0.62) | SLC7A5PTGS1ALPIPKMXIAP | |
| Hydrochloric Acid SCHEMBL31105583 | 0.98 | SLC7A5 (0.61) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL2310526 | 0.84 | SLC7A5 (0.83) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL43594 | 0.82 | SLC7A5 (0.62) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL231561 | 0.82 | SLC7A5 (0.62) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL838534 | 0.82 | SLC7A5 (0.62) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL43593 | 0.82 | SLC7A5 (0.62) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL231560 | 0.82 | SLC7A5 (0.62) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL309210 | 0.81 | SLC7A5 (0.70) | SLC7A5PTGS1ALPIPKMXIAP | |
| Hydrochloric Acid SCHEMBL1183792 | 0.81 | SLC7A5 (0.61) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 624 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4659023-A1 | METHOD OF PREDICTING SUCCESS OF A CANCER THERAPY | Immusmol SAS (FR) | 2025-12-10 | — | — | EP | claimed |
| US-12247320-B2 | Multivalent glycopeptides that tightly bind to carbohydrate-binding monoclonal antibody family PGT128 | BRANDEIS UNIVERSITY (US) | 2025-03-11 | — | — | US | claimed |
| US-20250041439-A1 | ANTIBODY-DRUG CONJUGATES | SPIREA LIMITED (GB) | 2025-02-06 | — | — | US | claimed |
| WO-2024241086-A1 | PEGYLATED BOVINE INTERFERON LAMBDA AND METHODS OF USE THEREOF | AMBRX, INC. (US) | 2024-11-28 | — | — | WO | claimed |
| WO-2024215515-A1 | DRUG LINKERS AND ANTIBODY CONJUGATES THEREOF | AMBRX, INC. (US) | 2024-10-17 | — | — | WO | claimed |
| WO-2024178310-A1 | TROP2-DIRECTED ANTIBODY-DRUG CONJUGATES AND USES THEREOF | AMBRX, INC. (US) | 2024-08-29 | — | — | WO | claimed |
| WO-2024178360-A2 | AURISTATIN ANALOGS AND ANTIBODY CONJUGATES THEREOF | AMBRX, INC. (US) | 2024-08-29 | — | — | WO | claimed |
| WO-2024161038-A1 | METHOD OF PREDICTING SUCCESS OF A CANCER THERAPY | IMMUSMOL SAS (FR) | 2024-08-08 | — | — | WO | claimed |
| EP-4404974-A1 | ANTIBODY-DRUG CONJUGATES | Spirea Limited (GB) | 2024-07-31 | — | — | EP | claimed |
| US-20230173092-A1 | ANTIBODY-DRUG CONJUGATES | SPIREA LIMITED (GB) | 2023-06-08 | — | — | US | claimed |
| WO-2007130453-A2 | NON-NATURAL AMINO ACID SUBSTITUTED POLYPEPTIDES | ALLOZYNE, INC. (US) | 2007-11-15 | — | — | WO | claimed |
| WO-2007103307-A2 | SITE-SPECIFIC INCORPORATION OF AMINO ACIDS INTO MOLECULES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2007-09-13 | — | — | WO | claimed |
| WO-2007090198-A2 | FLUORESCENT ASSAYS USING ORTHOGONAL TRNA - AMINOACYL SYNTHETASE PAIRS | ENCODE BIO, INC. (US) | 2007-08-09 | — | — | WO | claimed |
| US-7049336-B2 | Immunosuppressants; antiallergens; modulation serotonin concentration | MAX-DELBRUCK-CENTRUM FUR MOLEKULARC MEDIZIN (DE) | 2006-05-23 | — | — | US | claimed |
| EP-1521823-A2 | NEURONALLY EXPRESSED TRYPTOPHANE HYDROXYLASE AND ITS USE | Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch; (DE) | 2005-04-13 | — | — | EP | claimed |
| JP-2004507491-A | — | — | 2004-03-11 | — | — | JP | claimed |
| US-20040014656-A1 | Method for diagnosing neuronal deseases and for treating primary hemostasis deficiency | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2004-01-22 | — | — | US | claimed |
| WO-2004007704-A2 | NEURONALLY EXPRESSED TRYPTOPHANE HYDROXYLASE AND ITS USE | MAX DELBRÜCK CENTRUM FÜ MOLEKULARE MEDIZIN (MDC) BERLIN-BUCH (DE) | 2004-01-22 | — | — | WO | claimed |
| EP-1317265-A2 | METHOD FOR DIAGNOSING NEURONAL DISEASES AND FOR TREATING PRIMARY HEMOSTASIS DEFICIENCY | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) | 2003-06-11 | — | — | EP | claimed |
| WO-2002017891-A2 | METHOD FOR DIAGNOSING NEURONAL DISEASES AND FOR TREATING PRIMARY HEMOSTASIS DEFICIENCY | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2002-03-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12247320-B2 | Multivalent glycopeptides that tightly bind to carbohydrate-binding monoclonal antibody family PGT128 | CSGALNACT1, STT3A, GALNT14 | SLC7A5 449/4885PTGS1 3699/4885ALPI 2546/4885 |
| US-20230173092-A1 | ANTIBODY-DRUG CONJUGATES | CD44, CD47, FCGR3B | SLC7A5 70/4885PTGS1 4517/4885ALPI 2840/4885 |
| US-20250041439-A1 | ANTIBODY-DRUG CONJUGATES | CD44, CD47, FCGR3B | SLC7A5 70/4885PTGS1 4517/4885ALPI 2840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.